HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human ...

ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a ...

This experimental treatment is a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody aimed at fighting CLDN6-positive gynecologic and testicular cancers. The Phase 1 trial, which includes ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement -- First-in-human study will evaluate the safety, tolerability ...

Major milestones include dosing the first patient in the Phase 1 trial of CTIM-76, targeting CLDN6-positive cancers, and plans to begin a trial for CT-95 in Q2 2025. CEO Martin Lehr emphasized the ...

PHILADELPHIA, March 6, 2025 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery against membrane proteins, is pleased to announce that its out-licensed anti-Claudin 6 (CLDN6 ...

CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement SPRING HOUSE, Pa., March 13, 2025 /PRNewswire/ -- Third Arc Bio Inc., a ...

In January 2025, announced the first patient dosed in its Phase 1 trial evaluating CTIM-76 in patients with CLDN6-positive gynecologic and testicular cancers. In September 2024, announced an ...